JP2008522610A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008522610A5 JP2008522610A5 JP2007545022A JP2007545022A JP2008522610A5 JP 2008522610 A5 JP2008522610 A5 JP 2008522610A5 JP 2007545022 A JP2007545022 A JP 2007545022A JP 2007545022 A JP2007545022 A JP 2007545022A JP 2008522610 A5 JP2008522610 A5 JP 2008522610A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- human
- influenza virus
- sequence
- binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000712461 unidentified influenza virus Species 0.000 claims 41
- 210000004408 hybridoma Anatomy 0.000 claims 33
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 27
- 210000004027 cell Anatomy 0.000 claims 22
- 241001465754 Metazoa Species 0.000 claims 18
- 230000001225 therapeutic effect Effects 0.000 claims 17
- 239000003795 chemical substances by application Substances 0.000 claims 16
- 230000000069 prophylactic effect Effects 0.000 claims 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 12
- 230000009385 viral infection Effects 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 229940124597 therapeutic agent Drugs 0.000 claims 11
- 208000015181 infectious disease Diseases 0.000 claims 10
- 238000000034 method Methods 0.000 claims 10
- 208000024891 symptom Diseases 0.000 claims 10
- 206010022000 influenza Diseases 0.000 claims 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 108060003951 Immunoglobulin Proteins 0.000 claims 6
- 125000000539 amino acid group Chemical group 0.000 claims 6
- 102000018358 immunoglobulin Human genes 0.000 claims 6
- 238000012216 screening Methods 0.000 claims 6
- 210000004989 spleen cell Anatomy 0.000 claims 6
- 241000712431 Influenza A virus Species 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 230000029812 viral genome replication Effects 0.000 claims 5
- 238000012286 ELISA Assay Methods 0.000 claims 4
- 241000602333 H11N1 subtype Species 0.000 claims 4
- 241001616958 H13N6 subtype Species 0.000 claims 4
- 241000197305 H1N2 subtype Species 0.000 claims 4
- 241000197183 H2N3 subtype Species 0.000 claims 4
- 241000252845 H5N3 subtype Species 0.000 claims 4
- 241000252872 H6N1 subtype Species 0.000 claims 4
- 241000252866 H7N1 subtype Species 0.000 claims 4
- 241000252864 H7N2 subtype Species 0.000 claims 4
- 241000252868 H7N7 subtype Species 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 4
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 claims 4
- 230000007423 decrease Effects 0.000 claims 4
- 230000005764 inhibitory process Effects 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 206010011224 Cough Diseases 0.000 claims 3
- 241000827380 H11N2 subtype Species 0.000 claims 3
- 241000620997 H11N9 subtype Species 0.000 claims 3
- 206010019233 Headaches Diseases 0.000 claims 3
- 208000002979 Influenza in Birds Diseases 0.000 claims 3
- 206010028735 Nasal congestion Diseases 0.000 claims 3
- 206010068319 Oropharyngeal pain Diseases 0.000 claims 3
- 208000005141 Otitis Diseases 0.000 claims 3
- 201000007100 Pharyngitis Diseases 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 206010035664 Pneumonia Diseases 0.000 claims 3
- 206010037660 Pyrexia Diseases 0.000 claims 3
- 239000003443 antiviral agent Substances 0.000 claims 3
- 206010064097 avian influenza Diseases 0.000 claims 3
- 206010006451 bronchitis Diseases 0.000 claims 3
- 208000019258 ear infection Diseases 0.000 claims 3
- 231100000869 headache Toxicity 0.000 claims 3
- 206010025482 malaise Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims 3
- 201000009890 sinusitis Diseases 0.000 claims 3
- 206010014020 Ear pain Diseases 0.000 claims 2
- 241000252869 H3N8 subtype Species 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 101710085938 Matrix protein Proteins 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 101710132653 Protein M2 Proteins 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 229940072221 immunoglobulins Drugs 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 210000004400 mucous membrane Anatomy 0.000 claims 2
- 230000005727 virus proliferation Effects 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000001588 bifunctional effect Effects 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000005713 exacerbation Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 210000003928 nasal cavity Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 230000009261 transgenic effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63384604P | 2004-12-06 | 2004-12-06 | |
| US60/633,846 | 2004-12-06 | ||
| US72419805P | 2005-10-06 | 2005-10-06 | |
| US60/724,198 | 2005-10-06 | ||
| PCT/IB2005/004146 WO2006061723A2 (en) | 2004-12-06 | 2005-12-05 | Human monoclonal antibodies to influenza m2 protein and methods of making and using same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008522610A JP2008522610A (ja) | 2008-07-03 |
| JP2008522610A5 true JP2008522610A5 (https=) | 2009-01-29 |
| JP4881874B2 JP4881874B2 (ja) | 2012-02-22 |
Family
ID=36578283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007545022A Expired - Fee Related JP4881874B2 (ja) | 2004-12-06 | 2005-12-05 | インフルエンザｍ２タンパク質に対するヒトモノクローナル抗体及びその生産方法及びその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8124091B2 (https=) |
| EP (2) | EP1819732A2 (https=) |
| JP (1) | JP4881874B2 (https=) |
| KR (1) | KR20070085439A (https=) |
| CN (1) | CN101072795B (https=) |
| AU (1) | AU2005313026B2 (https=) |
| CA (1) | CA2585104A1 (https=) |
| TW (1) | TWI377212B (https=) |
| WO (1) | WO2006061723A2 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8753691B2 (en) * | 1999-06-01 | 2014-06-17 | American Silver, Llc | Antiviral colloidal silver composition |
| NZ585500A (en) * | 2007-11-12 | 2012-06-29 | Theraclone Sciences Inc | Antibodies which bind to an epitope in the extracellular domain of the matrix 2 ectodomain polypeptide of an influenza virus |
| CA2705289A1 (en) * | 2007-11-13 | 2009-05-22 | The Scripps Research Institute | Production of cytotoxic antibody-toxin fusion in eukaryotic algae |
| EP2065398A1 (en) | 2007-11-29 | 2009-06-03 | Cytos Biotechnology AG | Human monoclonal nicotine specific antibodies |
| US8658180B2 (en) * | 2008-08-15 | 2014-02-25 | Mark A. Miller | Vaccines against influenza virus |
| WO2010041702A1 (ja) * | 2008-10-08 | 2010-04-15 | 株式会社 ポッカコーポレーション | 抗鳥インフルエンザウイルス剤及び抗鳥インフルエンザウイルス剤含有製品 |
| TWI473621B (zh) * | 2008-11-12 | 2015-02-21 | Theraclone Sciences Inc | 供治療和診斷流感用之組成物和方法 |
| EP2346529B1 (en) * | 2008-11-12 | 2016-02-10 | Theraclone Sciences, Inc. | Human m2e peptide immunogens |
| CN101402677A (zh) * | 2008-11-19 | 2009-04-08 | 中国人民解放军军事医学科学院微生物流行病研究所 | 一种四分肽及其应用 |
| WO2010063675A1 (en) * | 2008-12-04 | 2010-06-10 | Cytos Biotechnology Ag | Fully human influenza m2 specific antibodies |
| WO2010110737A1 (en) * | 2009-03-23 | 2010-09-30 | Temasek Life Sciences Laboratory Limited | Monoclonal antibody against a conserved domain of m2e polypeptide in influenza viruses |
| JP2012527473A (ja) * | 2009-05-20 | 2012-11-08 | セラクローン サイエンシーズ， インコーポレイテッド | インフルエンザの治療および診断のための組成物および方法 |
| BRPI1010759B1 (pt) | 2009-06-11 | 2019-07-16 | Inter-University Research Institute Corporation Research Organization Of Information And Systems | Método para produzir uma proteína de interesse ou para obter uma suspensão de células de mamíferos capaz de produzir uma proteína de interesse, bem como vetor de expressão de proteína |
| CN102120759B (zh) * | 2010-01-07 | 2015-08-12 | 北京英诺泰生物技术有限公司 | 一种多肽及其衍生物与应用 |
| EP2552490A4 (en) * | 2010-03-26 | 2013-12-18 | Emergent Product Dev Gaithersburg Inc | INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF |
| US8809004B2 (en) | 2010-04-02 | 2014-08-19 | Idexx Laboratories, Inc. | Detection of feline immunodeficiency virus |
| WO2011130555A1 (en) * | 2010-04-16 | 2011-10-20 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Detection of h5n1 influenza infection |
| AU2011342161C1 (en) | 2010-12-15 | 2016-03-17 | Kyowa Kirin Co., Ltd. | Process for production of protein |
| SG193402A1 (en) * | 2011-03-15 | 2013-10-30 | Theraclone Sciences Inc | Compositions and methods for the therapy and diagnosis of influenza |
| HK1208355A1 (en) * | 2012-11-05 | 2016-03-04 | Georgia State University Research Foundation, Inc. | Universal influenza vaccine based on heterologous multiple m2e proteins |
| WO2014106021A1 (en) | 2012-12-27 | 2014-07-03 | Massachusetts Eye & Ear Infirmary | Treatment of rhinosinusitis with p-glycoprotein inhibitors |
| CN103901202B (zh) * | 2014-04-04 | 2015-08-12 | 中国人民解放军成都军区疾病预防控制中心 | 基于共有表位甲型流感病毒抗体通用型竞争性elisa检测方法 |
| WO2017123933A1 (en) | 2016-01-15 | 2017-07-20 | Massachusetts Eye And Ear Infirmary | Secreted p-glycoprotein is a non-invasive biomarker of chronic rhinosinusitis |
| CN108517315B (zh) * | 2018-03-30 | 2019-06-04 | 四川迈克生物新材料技术有限公司 | 抗人IgM单克隆抗体、其杂交瘤细胞株及应用 |
| CN109022366A (zh) * | 2018-08-16 | 2018-12-18 | 江南大学 | 一株分泌抗左旋咪唑单克隆抗体的杂交瘤细胞株及其应用 |
| US12295933B2 (en) | 2019-03-25 | 2025-05-13 | Massachusetts Eye And Ear Infirmary | Methods and compositions to treat and diagnose diseases or pathologies associated with inflammation of the sinuses and nasal cavity |
| WO2021201677A1 (en) | 2020-04-01 | 2021-10-07 | Kiadis Pharma Intellectual Property B.V. | Compositions and methods targeting influenza |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4036945A (en) | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
| US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5273876A (en) | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1990009441A1 (en) | 1989-02-01 | 1990-08-23 | The General Hospital Corporation | Herpes simplex virus type i expression vector |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0563296B1 (en) | 1990-12-20 | 1999-03-17 | Ixsys, Inc. | Optimization of binding proteins |
| GB9105383D0 (en) | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| WO1994012629A1 (en) | 1992-12-02 | 1994-06-09 | Baylor College Of Medicine | Episomal vectors for gene therapy |
| EP0728202A4 (en) | 1993-11-12 | 1997-04-23 | Univ Case Western Reserve | EPISOMIC EXPRESSION VECTOR FOR HUMAN GENE THERAPY |
| US5731172A (en) | 1994-03-09 | 1998-03-24 | Sumitomo Pharmaceuticals Company, Ltd. | Recombinant adenovirus and process for producing the same |
| US5604090A (en) | 1994-06-06 | 1997-02-18 | Fred Hutchinson Cancer Research Center | Method for increasing transduction of cells by adeno-associated virus vectors |
| US5693508A (en) | 1994-11-08 | 1997-12-02 | Chang; Lung-Ji | Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats |
| JP3770333B2 (ja) | 1995-03-15 | 2006-04-26 | 大日本住友製薬株式会社 | 組換えｄｎａウイルスおよびその製造方法 |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| US6590079B2 (en) | 1997-01-30 | 2003-07-08 | Ixsys, Incorporated | Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same |
| ES2255181T3 (es) | 1997-08-05 | 2006-06-16 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. | Antigeno inmunoprotector contra la gripe y su uso en vacunacion. |
| US6169175B1 (en) | 1997-08-06 | 2001-01-02 | Centers For Disease Control And Prevention | Preparation and use of recombinant influenza A virus M2 construct vaccines |
| US6531580B1 (en) | 1999-06-24 | 2003-03-11 | Ixsys, Inc. | Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| CA2398466A1 (en) | 2000-01-27 | 2001-08-02 | Medimmune, Inc. | Ultra high affinity neutralizing antibodies |
| CN1487996B (zh) | 2000-11-30 | 2010-06-16 | 米德列斯公司 | 用于生产人类抗体的转基因转染色体啮齿动物 |
| US7476536B2 (en) | 2001-05-11 | 2009-01-13 | Kirin Pharma Kabushiki Kaisha | Artificial human chromosome containing human antibody a light chain gene |
| KR20040111402A (ko) * | 2002-03-13 | 2004-12-31 | 기린 비루 가부시키가이샤 | 인플루엔자 м2 단백질에 대한 인간 모노클로날 항체 및그의 제조 및 사용 방법 |
-
2005
- 2005-12-05 EP EP05850822A patent/EP1819732A2/en not_active Withdrawn
- 2005-12-05 AU AU2005313026A patent/AU2005313026B2/en not_active Ceased
- 2005-12-05 EP EP10179368A patent/EP2295465B1/en not_active Expired - Lifetime
- 2005-12-05 CA CA002585104A patent/CA2585104A1/en not_active Abandoned
- 2005-12-05 JP JP2007545022A patent/JP4881874B2/ja not_active Expired - Fee Related
- 2005-12-05 WO PCT/IB2005/004146 patent/WO2006061723A2/en not_active Ceased
- 2005-12-05 KR KR1020077011773A patent/KR20070085439A/ko not_active Abandoned
- 2005-12-05 CN CN200580041805.XA patent/CN101072795B/zh not_active Expired - Fee Related
- 2005-12-05 US US11/577,695 patent/US8124091B2/en not_active Expired - Fee Related
- 2005-12-06 TW TW094143278A patent/TWI377212B/zh not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008522610A5 (https=) | ||
| US10815294B2 (en) | Neutralizing anti-influenza A virus antibodies and uses thereof | |
| US8871207B2 (en) | Neutralizing anti-influenza A virus antibodies and uses thereof | |
| WO2006061723B1 (en) | Human monoclonal antibodies to influenza m2 protein and methods of making and using same | |
| JP2005519619A5 (https=) | ||
| US20050170334A1 (en) | Human monoclonal antibodies to influenza M2 protein and methods of making and using same | |
| CN102216327A (zh) | 中和抗甲型流感病毒抗体及其用途 | |
| US20030219442A1 (en) | Human monoclonal antibodies to influenza M2 protein and methods of making and using same | |
| EP2793945B1 (en) | Antibodies useful in passive influenza immunization | |
| KR20140112495A (ko) | 인플루엔자 a 바이러스 특이적 항체 | |
| US8003106B2 (en) | Human monoclonal antibodies to influenza M2 protein and methods of making and using same | |
| HK1259389B (en) | Neutralizing anti-influenza a virus antibodies and uses thereof | |
| HK1259389A1 (en) | Neutralizing anti-influenza a virus antibodies and uses thereof | |
| HK1113684A (en) | Human monoclonal antibodies to influenza m2 protein and methods of making and using same | |
| HK1203410B (en) | Antibodies useful in passive influenza immunization |